|
| | Issue Date | Title | Contributor(s) | Type | Cat. |
| 1 | 2022 | Cognitive improvements accompanied with WPAI improvements in OCR-treated patients with RRMS: 96-week CASTING data | Vermersch, P.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Kuenzel, T.; Benedict, R. | Journal Contribution | M |
| 2 | 2022 | Efficacy and safety of ocrelizumab is maintained in patients with RRMS with suboptimal response to prior disease-modifying therapies: 4-year NEDA data from CASTING-LIBERTO | Oreja-Guevara, C.; Benedict, R. H.; Comi, G.; Cutter, G.; Kister, I.; Siva, A.; Wiendl, H.; VAN WIJMEERSCH, Bart; Wuerfel, J.; El Azzouzi, B.; Buffels, R.; Dirks, P.; Kuenzel, T.; Vermersch, P. | Journal Contribution | M |
| 3 | 2022 | Cognitive improvements in ocrelizumab-treated patients with relapsing-remitting multiple sclerosis: 96-week CASTING study data | Benedict, R. H.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Kuenzel, T.; Vermersch, P. | Journal Contribution | M |
| 4 | 2022 | Employment and cognitive improvements in ocrelizumab-treated patients with relapsing-remitting multiple sclerosis: 96-week CASTING study data | Wiendl, H.; Benedict, R. H.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Buffels, R.; Kuenzel, T.; Vermersch, P. | Journal Contribution | M |
| 5 | 2022 | Employment and Cognitive Improvements in Ocrelizumab-Treated Patients with Relapsing-Remitting Multiple Sclerosis: 96-Week CASTING Study Data | Wiendl, H.; Benedict, R.H.B.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Buffels, R.; Kuenzel, T.; Vermersch, P. | Conference Material | C2 |
| 6 | 2021 | Efficacy and safety of ocrelizumab in patients with RRMS with suboptimal response to prior disease-modifying therapies: 3-year data from CASTING and LIBERTO 1-year interim results | VAN WIJMEERSCH, Bart; Comi, G.; Oreja-Guevara, C.; Wiendl, H.; Wuerfel, J.; Buffels, R.; Dirks, P.; Kuenzel, T.; Kadner, K.; Vermersch, P. | Journal Contribution | M |
| 7 | 2020 | Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results) | Vermersch, P.; Eralinna, J.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Wei, W.; Comi, G. | Journal Contribution | M |
| 8 | 2020 | Ocrelizumab phase iiib efficacy from casting: 2-year neda (mri re-baselined) subgroup rates in rrms patients with a suboptimal response to prior dmts | Wiendl, H.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wuerfel, J.; Buffels, R.; Kadner, K.; Kuenzel, T.; Vermersch, P. | Journal Contribution | M |
| 9 | 2019 | Alemtuzumab improves outcomes in RRMS patients who switched from SC IFNB-1a: 6-year follow-up of CARE-MS I Patients (TOPAZ Study) | Montalban, X.; Barone, D.; Broadley, S.; Dive, D.; Hupperts, R. M.; Lycke, J.; Massacesi, L.; Naismith, R. T.; Nakamura, K.; Pandey, K.; Schippling, S.; Vermersch, P.; Wiendl, H.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 10 | 2019 | Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results) | Vermersch, P.; Eralinna, J. -P.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Kuhelj, R.; Wei, W.; Comi, G. | Journal Contribution | M |
| 11 | 2018 | Lack of apparent association between lymphocyte pharmacodynamics and clinical or MRI disease activity in alemtuzumab-treated relapsing-remitting Multiple Sclerosis patients through 6 years: CARE-MS extension | VAN WIJMEERSCH, Bart; Carraro, M.; Comi, G.; Izquierdo, G.; Kim, H. J.; Sharrack, B.; Tornatore, C.; Daizadeh, N.; Melanson, M.; Jacobs, Alessia; Wiendl, H. | Journal Contribution | M |
| 12 | 2018 | Lack of apparent association between lymphocyte repopulation kinetics and autoimmune events in alemtuzumab-treated patients with relapsing-remitting Multiple Sclerosis through 6 years: CARE-MS extension | Wiendl, H.; Carraro, M.; Comi, G.; Izquierdo, G.; Kim, H. J.; Sharrack, B.; Tornatore, C.; Daizadeh, N.; Melanson, M.; JACOBS, Andre; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 13 | 2018 | No correlation between lymphocyte repopulation kinetics and MS disease activity following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis | Wiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; JACOBS, Andre; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 14 | 2018 | No correlation between lymphocyte pharmacodynamics and autoimmune adverse events following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis | Wiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; Jacobs, Alessia; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 15 | 2018 | Alemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study) | VAN WIJMEERSCH, Bart; Barone, D.; Broadley, S.; Dive, D.; Hupperts, R. M. M.; Lycke, J.; Massacesi, L.; Montalban, X.; Naismith, R. T.; Pandey, K.; Schippling, S.; Vermersch, P.; Chung, L.; Daizadeh, N.; Rodriguez, C. E.; Nakamura, K.; Wiendl, H. | Journal Contribution | M |
| 16 | 2017 | Comparative clinical efficacy of alemtuzumab and ocrelizumab in patients with relapsing-remitting multiple sclerosis: Number needed to treat analyses | Comi, G.; Boster, A.; Alroughani, R.; Berkovich, R.; Izquierdo, G.; Kantor, D.; Laganke, C.; Limmroth, V.; Macdonell, R.; Moreau, T.; Sharrack, B.; Wiendl, H.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Melanson, M.; Freedman, M. S. | Journal Contribution | M |
| 17 | 2016 | Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatment | Bermel, R.; Comi, G.; Eralinna, J. -P.; Leist, T. P.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Bernasconi, C.; Buffels, R.; Csoboth, C.; Han, J.; Musch, B.; Vermersch, P. | Journal Contribution | M |
| 18 | 2015 | Characterizing the impact of teriflunomide on adaptive immune cell subsets, repertoire and function in patients with relapsing-remitting MS: TERI-DYNAMIC | Wiendl, H.; Gross, C. C.; Lindner, M.; Eschborn, M.; Weisser, L.; Posevitz-Fejfar, A.; Schulte-Mecklenbeck, A.; VAN WIJMEERSCH, Bart; Hupperts, R.; Lunven, C.; Brette, S.; Turner, T. J.; Klotz, L. | Journal Contribution | M |
Loading...
5
0
5
0
false